» Articles » PMID: 2317815

Effects of Androgen Withdrawal on the Stem Cell Composition of the Shionogi Carcinoma

Overview
Journal Cancer Res
Specialty Oncology
Date 1990 Apr 15
PMID 2317815
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

The parent Shionogi mouse mammary carcinoma is androgen dependent but cells that survive hormone withdrawal progress and give rise to an androgen-independent tumor. To determine whether renewed growth might be attributed to the persistence or partial recovery of an androgenic stimulus, we compared the amount of dihydrotestosterone and nuclear androgen receptor in parent and recurrent tumors. The whole tissue concentration of dihydrotestosterone in the parent tumor before castration was 1.40 +/- 0.46 (SE) as compared with 0.22 +/- 0.10 pmol/mg of DNA in the recurrent tumor. The initial concentration of nuclear androgen receptor in the parent was 0.65 +/- 0.12 pmol/mg of DNA; this was reduced to zero within 24 h after castration. Also in keeping with the androgen independence, no receptor was detected in the nuclear fraction of the recurrent carcinoma. In an attempt to relate malignant potential to nonhormonal factors associated with progression, we compared the proportions of androgen-dependent and -independent tumorigenic (stem) cells in parent and recurrent tumors using an in vivo limiting dilution assay. The difference observed, i.e., one stem cell per 4000 tumor cells in the parent versus one stem cell per 200 tumor cells in the recurrent carcinoma, was consistent with a marked enrichment of stem cells in the latter. The proportion of androgen-independent stem cells was also determined by assaying tumor takes in female hosts. The difference, i.e., one stem cell per 370,000 tumor cells in the parent versus one stem cell per 800 tumor cells in the recurrent carcinoma, demonstrated a striking 500-fold increase in androgen-independent stem cells resulting from androgen withdrawal. Unexpectedly, no enrichment of androgen-independent stem cells was evident in regressing parent tumors; rather, the proportion of such cells was very small, i.e., one androgen-independent stem cell per 2,200,000 regressing parent cells. This finding implies that the androgen-independent state of cells which survive androgen withdrawal may result from the ability of a small number of initially androgen-dependent stem cells to adapt to an altered hormone environment.

Citing Articles

The effect of tumor composition on the success of adaptive therapy: The case of metastatic Castrate-Resistant Prostate Cancer.

Salvioli M, Vandelaer L, Baena E, Schneider K, Cavill R, Stankova K PLoS One. 2024; 19(9):e0308173.

PMID: 39325718 PMC: 11426540. DOI: 10.1371/journal.pone.0308173.


Current Clinical Aspects of Androgen Deprivation Therapy for Locally Advanced and Metastatic Prostate Cancer: A Scoping Review for Urologists and Medical Providers.

Kassab J, Meeks R, de Riese W Res Rep Urol. 2024; 16:187-193.

PMID: 39310217 PMC: 11414637. DOI: 10.2147/RRU.S467344.


Treatment of evolving cancers will require dynamic decision support.

Strobl M, Gallaher J, Robertson-Tessi M, West J, Anderson A Ann Oncol. 2023; 34(10):867-884.

PMID: 37777307 PMC: 10688269. DOI: 10.1016/j.annonc.2023.08.008.


How can we best manage biochemical failure after radical prostatectomy?.

Kim W, Kim J, Kim W Investig Clin Urol. 2022; 63(6):592-601.

PMID: 36347548 PMC: 9643724. DOI: 10.4111/icu.20220294.


Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain.

Bonfill-Cosp X, Auladell-Rispau A, Gich I, Zamora J, Saiz L, Pijoan J F1000Res. 2022; 10:1069.

PMID: 36330533 PMC: 9614286. DOI: 10.12688/f1000research.53875.2.